TRIPENICOL S Antifungal Solution Recalled for CGMP Deviations
Blaine Labs Inc is recalling TRIPENICOL S Antifungal Solution (Undecylenic Acid 25%) because the firm discontinued required stability testing for products still on the market within their expiration date.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall involving CGMP deviations (discontinuation of stability testing). No illnesses or injuries are reported in the source text, and the hazard is a manufacturing process deviation rather than confirmed product contamination or defect. FDA Class II recalls without reported illness or injury typically fall in the Moderate range.
Plain-English summary
Blaine Labs Inc is recalling TRIPENICOL S Antifungal Solution (Undecylenic Acid 25%), 1.25 FL OZ (37.5 mL) bottles, NDC 73352-550-01, Lot #BL3411R with expiration date 6/8/2027. The recall is due to Current Good Manufacturing Practice (CGMP) deviations: the firm discontinued required stability testing for products that remain on the market and are still within their expiration date.
A total of 144 bottles were distributed nationwide in the USA. Consumers who have purchased this product should stop using it and consult their healthcare provider with any questions or concerns.
The recalled product
- Product
- TRIPENICOL S (UNDECYLENIC ACID)
- Brand
- TRIPENICOL S
- Manufacturer
- Blaine Labs Inc
- Category
- Drug — OTC Antifungal Topical
- Affected units
- 144
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #BL3411R
- Exp 6/8/2027
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 8 recalled by Blaine Labs Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 8 products in this recall →Related recalls
Same manufacturer · Blaine Labs Inc
See all →- ModerateRevitaderm Wound Care Benzalkonium Chloride OTC Drug Recall
FDA (Drugs) · 2026-07-08
- ModerateTerpenicol Antifungal Solution Recalled for CGMP Deviations
FDA (Drugs) · 2026-07-08
- Moderatevite20 Antifungal Cream recalled due to stability testing deviations
FDA (Drugs) · 2026-07-08
- ModerateTERPENICOL Antifungal Cream Recalled for CGMP Deviations
FDA (Drugs) · 2026-07-08
- ModerateFungal Fusion antifungal kit recalled for discontinued stability testing
FDA (Drugs) · 2026-07-08
Same hazard · cgmp deviation
See all →- SevereBaxter Recalls Vasopressin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateLexia LLC Recalls Broadway Joe's Pain Cream Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
Similar recalls
- ModerateTriamcinolone Acetonide Lotion Recalled for cGMP Deviations
FDA (Drugs) · 2022-03-30
- ModerateDiclofenac Sodium Topical Solution Recalled for Manufacturing Compliance Deviations
FDA (Drugs) · 2022-03-30
- ModerateDiclofenac Sodium Topical Solution recalled by Teligent Pharma
FDA (Drugs) · 2022-03-30
- SevereTri-Coast Pharmacy Recalls Dexpanthenol Due to Sterility Concerns
FDA (Drugs) · 2017-01-11
- ModerateClonidine HCl USP Recalled Due to Missing Stability Data
FDA (Drugs) · 2018-02-28
- ModerateAscend Recalls Cephalexin Oral Suspension Due to CGMP Deviations
FDA (Drugs) · 2021-02-24